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background: Cardiac allograft vasculopathy (CAV) is the leading cause of graft failure and death in heart transplant (HTx) recipients. However, 
the association between the etiology of heart failure (ischemic [ICM] or non-ischemic cardiomyopathy [non-ICM]) that led to HTx and progression 
of CAV, and adverse events after HTx has not been explored. We examined whether prior history of ICM or non-ICM contributes more to coronary 
atherosclerotic plaque progression and adverse events in HTx subjects.
Methods: We retrospectively included 165 HTx patients, who were followed-up with at least two intravascular ultrasound (IVUS) examinations post-
HTx, and grouped them into ICM (n = 46) or non-ICM (n = 119). Coronary artery plaque volume was analyzed using IVUS and cardiovascular event 
data was collected from medical records of all the study subjects.
results: ICM patients had a significantly greater plaque volume at follow-up IVUS examination (p = 0.015) compared with non-ICM patients. After 
multivariate adjustment for traditional coronary risk factors, ICM was significantly associated with plaque progression (OR 2.76; CI 1.04-8.26; p = 
0.03). Also, ICM was associated with significantly lower cardiovascular event-free survival (Figure), and higher event rate after HTx in multivariate 
analysis (HR 2.05, 95% CI 1.03-4.04, p = 0.04).
conclusions: Our study demonstrates that ischemic etiology of cardiomyopathy that led to HTx may be an independent predictor of plaque 
progression and higher event rate after HTx.
